Those fast-and-furious rumors about Chris Viehbacher's impending ouster at Sanofi? The new round of chatter about Viehbacher's replacement is almost as intense. Bloomberg has a list of healthcare execs said to be up for the job, and they span a who's who of Big Pharma companies.
Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding.
The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.
Takeda COO Christophe Weber announced a revamped management structure in September that he is building in an effort to revive the Japanese drugmaker. And from the company's just-released 6-month earnings report, the reason the revamp is needed is apparent.
More than three years after inking a $750 million pact to develop Intra-Cellular's PDE1 inhibitors for cognitive impairment caused by schizophrenia, Takeda is out.
That scary $9 billion damages award a Louisiana jury slapped on Takeda and Eli Lilly earlier this year? A U.S. district judge slashed the bill by more than 99%, saying the new amount is the biggest award allowed under current law.
It took a while, but San Diego-based Orexigen has just earned a $70 million milestone from its deal with Takeda on the obesity drug Contrave.
There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.
Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.
Sucampo and Takeda may not be the first to launch a DTC campaign for a chronic idiopathic constipation (CIC) treatment. But the team, which markets Amitiza, is doing things a little differently.